Ryman Healthcare schedules November 25 results for Ryman Healthcare stock

Published on 10/17/2026 at 19:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2026 revenue was NZD 849.10 million. Ryman Healthcare stock was last at NZD 1.83 on October 16, 2026, up 2.23 percent on NZX.

Results date and valuation

Ryman Healthcare will report half-year results on November 25, 2026.
Fiscal 2026 revenue reached NZD 849.10 million, up 10.00 percent.
Ryman Healthcare stock was last at NZD 1.83 on October 16, 2026 at 4:59 p.m. NZDT on the NZX, up 2.23 percent versus the prior close of NZD 1.79.
Market capitalization was NZD 1.9 billion and the price-to-earnings ratio was minus 11.12 on October 16, 2026.

RYM, NZRYME0001S4, Illustration mit AI erstellt.

Ryman Healthcare schedules its half-year results for November 25, 2026, according to NZX in an announcement dated October 14, 2026. The report will cover the six months to September 30, 2026 and will be followed by an investor briefing. Ryman Healthcare stock was last at NZD 1.83 on October 16, 2026 at 4:59 p.m. NZDT on the NZX, up 2.23 percent versus the prior close of NZD 1.79.

Revenue and cash flow reset

The latest full-year operating picture shows a business moving toward cash generation. Kapitales Research reported on September 24, 2026 that operating revenue reached NZD 849.10 million in fiscal 2026, up 10.00 percent. Free cash flow improved to NZD 188.30 million from a NZD 94.20 million outflow in fiscal 2025.

The same report put fiscal 2026 operating EBITDAF at NZD 88.30 million, nearly double the prior-year figure. It also described 325 occupation right agreement sales in the first quarter of fiscal 2027, including 265 resales and 60 new sales. The company operates retirement villages and aged-care facilities in New Zealand and Victoria, Australia, according to its investor information.

Price position on October 16

The NZX price of NZD 1.83 stood NZD 1.22, or 40.00 percent, below the 52-week high of NZD 3.05 and 10.24 percent above the low of NZD 1.66. Trading volume was 1,451,529 shares against an average of 1,867,023 shares. The latest price therefore sat below the yearly midpoint while remaining above the 52-week low.

Valuation and upcoming date

Market capitalization was NZD 1.9 billion on October 16, 2026, while the price-to-earnings ratio was minus 11.12. The scheduled November 25 results are the next dated company event and will provide the first reported period covering the six months to September 30, 2026. The NZX announcement also set an 11:00 a.m. NZT investor briefing for that date.

Comparison with peers

Ryman Healthcare (NZX, NZD): plus 2.23 percent, P/E minus 11.12, market capitalization NZD 1.9 billion
Summerset Group Holdings (NZX, NZD): plus 2.22 percent, P/E 5.52, market capitalization NZD 1.7 billion
Oceania Healthcare (NZX, NZD): plus 1.53 percent, P/E 5,943.34, market capitalization NZD 481.6 million

What comes next

The November report will put the recent cash-flow improvement against the companys development pace and sales pipeline. For investors, the key measurable points are revenue conversion, operating earnings and the path from positive fiscal 2026 free cash flow toward the next reporting period.

Stock and reporting date

The next results date is November 25, 2026, while the NZX price was last at NZD 1.83 on October 16, 2026 at 4:59 p.m. NZDT, up 2.23 percent versus the prior close of NZD 1.79.